Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocolSarah Nikiforow, Susan E. Prockop, Koen van Besien et al.|Blood Advances|2024Cited by 23
Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) Following Solid Organ (SOT) or Allogeneic Hematopoietic Cell Transplants (HCT) Treated with Tabelecleucel on an Expanded Access ProgramSusan E. Prockop, Sarah Nikiforow, Ran Reshef et al.|Blood|2019Cited by 9
Long-Term Outcomes of Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Solid Organ Transplant or Allogeneic Hematopoietic Cell Transplant Treated with Tabelecleucel in a Multicenter Expanded Access Program StudySusan E. Prockop, Sarah Nikiforow, Ran Reshef et al.|Transplantation and Cellular Therapy|2020Cited by 3
Outcomes After Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation with Total Lymphoid Irradiation and Anti-Thymocyte Globulin in Lymphoid Malignancies After Failed Autologous TransplantationAbraham S. Kanate, Robert Lowsky, Bradley Efron et al.|Transplantation and Cellular Therapy|2013Cited by 0